Direct-to-Phase II: Small Molecules with Broad-Spectrum Antifungal Activity for Safe Human Use
This opportunity solicits Direct-to-Phase II proposals to advance small-molecule candidates that are ready for Phase II testing, focusing on broad-spectrum, fungicidal activity against clinically relevant fungal pathogens while minimizing toxicity to humans. The primary goal is to identify a safe antifungal small molecule suitable for patient use and capable of achieving FDA clearance.
This topic is intended for technology proven ready to move directly into Phase II and accepts Direct to Phase II proposals only. The proposed research will focus on identifying compounds with broad-spectrum activity against clinically relevant fungal pathogens while minimizing toxicity to humans…
Funding Source
Dates
Documents
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers